Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study
Wendy E Hague, John Simes, Adrienne Kirby, Anthony C Keech, Harvey D White, David Hunt, Paul J Nestel, David M Colquhoun, Helen Pater, Ralph A Stewart, David R Sullivan, Peter L Thompson, Malcolm West, Paul P Glasziou, Andrew M Tonkin
CIRCULATION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2016
BACKGROUND: We aimed to assess the long-term effects of treatment with statin therapy on all-cause mortality, cause-specific mortality, and cancer incidence from extended follow-up of the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial. METHODS AND RESULTS: LIPID initially compared pravastatin and placebo over 6 years in 9014 patients with previous coronary heart disease. After the double-blind period, all patients were offered open-label statin therapy. Data were obtained over a further 10 years from 7721 patients, by direct contact for 2 years, by questionnaires thereafter, and from mortality and cancer registries. During extended follow-up, 85% assigned pravastat..View full abstract
Awarded by National Health and Medical Research Council
The study was designed, conducted, analyzed, and reported by the investigators and coordinated by the NHMRC Clinical Trials Centre under the auspices of the National Heart Foundation of Australia, independently of funders of the study. The study drug (including placebo) and financial support for the study were provided by Bristol-Myers Squibb for the first 8 years. Subsequently, funding was from National Health and Medical Research Council research grants 1037786, 1010279, and 490968.